Literature DB >> 19279450

Efavirenz dose reduction to 200 mg once daily in a patient treated with rifampicin.

Matthijs van Luin, Anne-Marie Brouwer, Andre van der Ven, Wiel de Lange, Ron H N van Schaik, David M Burger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19279450     DOI： 10.1097/QAD.0b013e32832914a3

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  4 in total

1.  Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers.

Authors:  Awewura Kwara; Karen T Tashima; Julie B Dumond; Pamela Poethke; Jaclyn Kurpewski; Angela D M Kashuba; Michael H Court; David J Greenblatt
Journal:  Antimicrob Agents Chemother       Date:  2011-04-25       Impact factor: 5.191

2.  Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy.

Authors:  Awewura Kwara; Margaret Lartey; Kwamena W Sagoe; Michael H Court
Journal:  AIDS       Date:  2011-01-28       Impact factor: 4.177

3.  CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.

Authors:  Awewura Kwara; Margaret Lartey; Kwamena W C Sagoe; Ernest Kenu; Michael H Court
Journal:  AIDS       Date:  2009-10-23       Impact factor: 4.177

Review 4.  Neurological and psychiatric adverse effects of antiretroviral drugs.

Authors:  Michael S Abers; Wayne X Shandera; Joseph S Kass
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.